[2-[(11R,16R,17R)-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-5,6,7,8,9,11,12,14,15,16-decahydro-4H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: [2-[(11R,16R,17R)-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-5,6,7,8,9,11,12,14,15,16-decahydro-4H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate
• 化学式: C₂₄H₃₄O₆
• 分子量: 418.5
• InChiKey: VYDRQXWBVHHFMM-WREZQBRESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• [EN] METHODS AND USE OF BIFUNCTIONAL ENZYME-BUILDING CLAMP-SHAPED MOLECULES<br/>[FR] PROCÉDÉS ET UTILISATION DE MOLÉCULES EN FORME DE PINCE GÉNÉRANT UNE ENZYME BIFONCTIONNELLE
  申请人：UNIV PENNSYLVANIA

  公开号：WO2012125913A1

  公开（公告）日：2012-09-20

  This invention is in the fields of cancer therapy. More particularly it concerns compounds which are useful agents for inhibiting cell proliferative disorders, especially those disorders characterized by over activity and/or inappropriate activity of a EGFR, including EGFR-related cancers, and methods for treating these disorders.

  这项发明涉及癌症治疗领域。更具体地，它涉及一些化合物，这些化合物是用于抑制细胞增殖异常的有效药物，特别是那些由EGFR过度活跃和/或不适当活跃引起的疾病，包括EGFR相关的癌症，并提供了治疗这些疾病的方法。
• MUTATION MIMICKING COMPOUNDS THAT BIND TO THE KINASE DOMAIN OF EGFR
  申请人：Berezov Alan

  公开号：US20140135298A1

  公开（公告）日：2014-05-15

  This invention is in the fields of cancer therapy. More particularly it concerns compounds which are useful agents for treating cell proliferative disorders, especially those disorders characterized by over activity and/or inappropriate activity of a EGFR, including EGFR-related cancers, particularly for expanding the efficacy of drugs previously developed for this purpose, and for methods of treatments using the compounds for this purpose.

  这项发明涉及癌症治疗领域。更具体地说，它涉及化合物，这些化合物是用于治疗细胞增殖性疾病的有用药剂，特别是那些以EGFR的过度活动和/或不适当活动为特征的疾病，包括EGFR相关癌症，特别是为了扩大先前为此目的开发的药物的功效，并使用这些化合物进行治疗的方法。
• METHODS AND USE OF BIFUNCTIONAL ENZYME-BUILDING CLAMP-SHAPED MOLECULES
  申请人：The Trustees of The University of Pennsylvania

  公开号：EP2685980B1

  公开（公告）日：2017-12-06
• Combination of IFN-gamma with Anti-ERBB Antibody for the Treatment of Cancers
  申请人：Greene Mark

  公开号：US20180057603A1

  公开（公告）日：2018-03-01

  The present invention provides a fusion proteins comprising (a) a first stretch of consecutive amino acids, the sequence of which is the sequence of an anti-p185her2/neu polypeptide or an anti-EGFR polypeptide; (b) a second stretch of consecutive amino acids, the sequence of which is the sequence of a polypeptide capable of binding at least one polypeptide other than p185her2/neu or EGFR; and (c) a third stretch of consecutive amino acids, the sequence of which comprises the sequence of a biologically active portion of interferon-gamma (IFNγ), wherein (b) is located at the carboxy-terminal end of (a), and (c) is located at the carboxy-terminal end of (b). The present invention provides methods and compositions treating or preventing cancer and for sensitizing cancer cells to radiation or a chemotherapeutic agent, which comprises administering i) an anti-p185her2/neu antibody, an anti-EGFR antibody or an erbB kinase inhibitor and interferon-gamma (IFNγ); or ii) a fusion protein of the invention.
• METHODS OF INCREASING RESPONSE TO CANCER RADIATION THERAPY
  申请人：The Trustees of the University of Pennsylvania

  公开号：US20220401753A1

  公开（公告）日：2022-12-22

  Disclosed herein are methods of increasing response to radiation therapy in subjects afflicted with cancer. In some embodiments, the method comprises reducing the ability of an immune suppressor cell (e.g., MDSC) to migrate to the microenvironment of the cancer. In some embodiments, the method further comprises suppressing the migration of the immune suppressor cell to a non-malignant cell and/or suppressing the malignant transformation of the non-malignant cells.